Influence of Hematocrit Level on the Visibility of the Venous Network in Magnetic Susceptibility Imaging

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05192135

Acronym

HEMAT_SWI

Enrollment

Registered

2022-01-14

Start date

2021-09-13

Completion date

2023-12-31

Last updated

2023-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

Magnetic susceptibility imaging is a magnetic resonance imaging (MRI) technique that uses the magnetic properties of tissues and the BOLD (blood oxygen level-dependent) effect. It allows a better visualization of venous structures and hemorrhagic lesions. These sequences are now used in clinical routine. The extreme sensitivity of these sequences to the oxy/deoxyhemoglobin ratio makes it possible to describe a new MRI semiology, particularly in the context of cerebral ischemia. The interest of the analysis of the venous network signal, which can reflect cerebral perfusion, has been reported. However, the influence of the hematocrit level on the signal of the venous network in magnetic susceptibility imaging has not been evaluated at present. It seems important to better define the influence of hematocrit level on the signal of the veins with this sequence to avoid potential diagnostic errors.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient whose age ≥ 18 years * Patient referred to GHPSJ for suspected stroke * Patient who had a brain MRI including the magnetic susceptibility sequence * Patient for whom a blood count with hematocrit was performed at the same time (within 7 days between the MRI and the blood test) * French-speaking patient

Exclusion criteria

* Patient under guardianship or curatorship * Patient deprived of liberty * Patient under court protection * Elimination of potential biases: recent injection (48 h) of gadolinium, pathology likely to modify the venous signal in magnetic susceptibility imaging (notably arterial occlusion or stenosis), high flow oxygenation, sickle cell disease, thalassemia. * Patient objecting to the use of his/her data for this research

Design outcomes

Primary

Measure	Time frame	Description
Specific influence of the hematocrit level on the visibility of the venous network	Day 1	This outcome corresponds to the visibility of the venous network in magnetic susceptibility imaging using a visual scale allowing comparison between patients with normal hematocrit, anemia or polycythemia.

Secondary

Measure	Time frame	Description
Inter-observer agreement of the visual analysis of the venous network	Day 1	This outcome corresponds to the correlation of visual scales between different observers.

Countries

France

Outcome results